Telix Pharmaceuticals Financials
TLX Stock | 25.74 0.80 3.21% |
Operating Margin 0.0949 | PE Ratio 170.2 | Profit Margin 0.0762 | EPS Estimate Current Year 0.1983 | Return On Equity 0.2049 |
Telix | Select Account or Indicator |
Please note, the imprecision that can be found in Telix Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Telix Pharmaceuticals. Check Telix Pharmaceuticals' Beneish M Score to see the likelihood of Telix Pharmaceuticals' management manipulating its earnings.
Telix Pharmaceuticals Stock Summary
Telix Pharmaceuticals competes with Aneka Tambang, Commonwealth Bank, Commonwealth Bank, Australia, and ANZ Group. Telix Pharmaceuticals is entity of Australia. It is traded as Stock on AU exchange.Foreign Associate | USA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | Australia Stock View All |
Exchange | Australian Securities Exchange |
ISIN | AU000000TLX2 |
Business Address | 55 Flemington Road, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | telixpharma.com |
Phone | 61 3 9093 3855 |
You should never invest in Telix Pharmaceuticals without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Telix Stock, because this is throwing your money away. Analyzing the key information contained in Telix Pharmaceuticals' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Telix Pharmaceuticals Key Financial Ratios
Telix Pharmaceuticals' financial ratios allow both analysts and investors to convert raw data from Telix Pharmaceuticals' financial statements into concise, actionable information that can be used to evaluate the performance of Telix Pharmaceuticals over time and compare it to other companies across industries.Revenue | 496.66 M | ||||
Gross Profit | 98.54 M | ||||
EBITDA | 22.97 M | ||||
Net Income | 5.21 M | ||||
Total Asset | 398.3 M |
Telix Pharmaceuticals Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 102.6M | 164.4M | 109.8M | 260.6M | 398.3M | 418.2M | |
Net Debt | (42.5M) | (75.7M) | (19.5M) | (105.9M) | (105.8M) | (100.5M) | |
Retained Earnings | (48.1M) | (93.0M) | (173.5M) | (272.8M) | (263.7M) | (250.5M) | |
Accounts Payable | 7.0M | 5.8M | 11.9M | 16.8M | 32.8M | 34.5M | |
Cash | 44.6M | 77.9M | 22.0M | 116.3M | 123.2M | 63.5M | |
Net Receivables | 13.0M | 14.2M | 20.8M | 39.4M | 64.8M | 68.0M | |
Total Liab | 31.9M | 84.4M | 106.2M | 178.4M | 249.4M | 261.9M | |
Total Current Assets | 58.7M | 93.6M | 47.5M | 173.2M | 224.8M | 236.1M | |
Common Stock | 115.9M | 167.1M | 170.8M | 371.0M | 446.3M | 468.6M | |
Other Current Liab | 3.2M | 10.1M | 19.3M | 55.8M | 100.5M | 105.5M | |
Other Liab | 20.3M | 57.4M | 67.8M | 80.0M | 92.0M | 96.6M | |
Net Tangible Assets | 28.1M | 19.8M | (53.6M) | 21.0M | 18.9M | 10.2M | |
Other Assets | 82K | 183K | 212K | 4.0M | 4.6M | 4.8M | |
Long Term Debt Total | 1.6M | 1.4M | 1.9M | 9.8M | 11.3M | 11.8M | |
Inventory | 542K | 633K | 3.5M | 8.5M | 17.3M | 18.2M | |
Other Current Assets | 530K | 859K | 1.2M | 9.1M | 19.5M | 20.5M | |
Net Invested Capital | 70.8M | 79.4M | 2.2M | 83.3M | 158.1M | 166.0M | |
Short Long Term Debt | 469K | 264K | 19K | 964K | 867.6K | 911.0K | |
Net Working Capital | 48.1M | 73.7M | 9.6M | 87.7M | 67.4M | 56.9M | |
Short Term Debt | 490K | 767K | 632K | 641K | 1.6M | 874.9K | |
Intangible Assets | 41.9M | 59.2M | 55.7M | 59.0M | 104.8M | 56.3M | |
Long Term Debt | 292K | 95K | 0.0 | 3.3M | 8.2M | 8.6M | |
Capital Stock | 115.9M | 167.1M | 170.8M | 371.0M | 446.3M | 246.2M |
Telix Pharmaceuticals Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 2.4M | 1.2M | 189K | 406K | 13.1M | 13.8M | |
Operating Income | (40.3M) | (49.3M) | (81.2M) | (73.2M) | 51.9M | 54.5M | |
Ebitda | (36.2M) | (44.9M) | (70.1M) | (92.8M) | 23.0M | 24.1M | |
Income Before Tax | (42.8M) | (60.3M) | (99.0M) | (98.6M) | 3.1M | 3.2M | |
Net Income | (27.9M) | (44.9M) | (80.5M) | (104.1M) | 5.2M | 5.5M | |
Income Tax Expense | (14.9M) | (15.4M) | (18.5M) | 5.5M | (2.1M) | (2.2M) | |
Total Revenue | 3.5M | 5.2M | 7.6M | 160.1M | 496.7M | 521.5M | |
Gross Profit | (11.9M) | (16.9M) | (29.8M) | 29.3M | 308.5M | 323.9M | |
Ebit | (40.4M) | (49.8M) | (75.2M) | (98.2M) | 16.2M | 17.0M | |
Research Development | 21.2M | 23.1M | 34.1M | 57.9M | 128.8M | 135.3M | |
Cost Of Revenue | 15.4M | 22.1M | 37.4M | 130.8M | 188.2M | 197.6M | |
Tax Provision | (3.3M) | (3.0M) | 45K | 5.5M | (2.1M) | (2.0M) | |
Net Interest Income | (2.3M) | (1.1M) | (5.2M) | (6.7M) | (12.8M) | (12.1M) | |
Interest Income | 2.4M | 67K | 163K | 1K | 1.0M | 626.2K |
Telix Pharmaceuticals Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | 18.8M | 33.3M | (55.9M) | 94.3M | 6.9M | 6.6M | |
Net Borrowings | (1.2M) | (904K) | (936K) | 1.7M | 2.0M | 2.1M | |
Depreciation | 4.2M | 4.9M | 5.2M | 5.4M | 6.9M | 7.3M | |
Other Non Cash Items | 9.7M | 18.7M | 31.5M | 41.0M | 60.5M | 63.5M | |
Capital Expenditures | 468K | 322K | 1.3M | 13.9M | 10.8M | 11.3M | |
Net Income | (27.9M) | (44.9M) | (80.5M) | (104.1M) | 5.2M | 5.5M | |
Change To Netincome | 659K | 10.2M | 18.6M | 35.7M | 41.1M | 43.2M | |
Investments | (468K) | (1.1M) | (2.7M) | (17.0M) | (25.5M) | (24.2M) | |
Free Cash Flow | (23.8M) | 1.6M | (60.7M) | (77.8M) | 13.1M | 13.7M | |
End Period Cash Flow | 44.6M | 77.9M | 22.0M | 116.3M | 123.2M | 72.1M |
Telix Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Telix Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Telix Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Telix Pharmaceuticals competition to find correlations between indicators driving Telix Pharmaceuticals's intrinsic value. More Info.Telix Pharmaceuticals is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers reporting about 0.39 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Telix Pharmaceuticals is roughly 2.57 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Telix Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Telix Pharmaceuticals Systematic Risk
Telix Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Telix Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Telix Pharmaceuticals correlated with the market. If Beta is less than 0 Telix Pharmaceuticals generally moves in the opposite direction as compared to the market. If Telix Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Telix Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Telix Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Telix Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Telix Pharmaceuticals Common Stock Shares Outstanding Over Time
Telix Pharmaceuticals December 18, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Telix Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Telix Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Telix Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Telix Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Telix Pharmaceuticals's daily price indicators and compare them against related drivers.
Downside Deviation | 2.12 | |||
Information Ratio | 0.1848 | |||
Maximum Drawdown | 12.13 | |||
Value At Risk | (3.31) | |||
Potential Upside | 4.04 |
Additional Tools for Telix Stock Analysis
When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.